Received Sep 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC | PNEUMO (PREVNAR) | PFIZER\WYETH | UNK | — | — |
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | — |
No additional AE; Inbound transfer from a Specialist. A pharmacist is reporting administering CAPVAXIVE today after the patient has already received PREVNAR 20 IN March 2025. See request case 02855367. Patient is 60 years old with unknown chronic medical conditions/im; This spontaneous report was received from a pharmacist and refers to a 60-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions included unknown chronic medical conditions/immunocompromised. Concomitant therapies were not reported. In March 2025, the patient received Prevnar 20 (Pneumococcal vaccine conj 20v (CRM197)) (lot # and expiration date were not reported). On 12-Aug-2025, the patient was vaccinated with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (lot # and expiration date were not reported) (inappropriate schedule of product administration). The reporter inquired if this is "ok" or are there any concern to be aware of. No additional AE (no adverse event).
Immunocompromised